natgillin/translations-raw huggingface dataset:
Growth factor support or transfusion support was necessary in 5.1% and 5.5% of patients, respectively (see section 4.2). 
Podpora z dajanjem rastnega faktorja je bila potrebna pri 5,1% bolnikov, dajanje transfuzij pa pri 5,5% bolnikov (glejte poglavje 4.2).
The total dose of doxorubicin hydrochloride must also take into account any previous (or concomitant) therapy with cardiotoxic compounds such as other anthracyclines/anthraquinones or e.g., 5-fluorouracil. 
Pri celokupnem odmerku doksorubicinijevega klorida morate upoštevati tudi morebitno predhodno ali sočasno zdravljenje s kardiotoksičnimi spojinami, npr. z drugimi antraciklini ali antrakinoni ali npr. 5-fluorouracilom.
In those patients who experience an infusion reaction, the method of infusion should be modified as follows: 
Pri bolnicah z infuzijsko reakcijo prilagodite način infundiranja zdravila, kot sledi:
Caelyx is also used to produce an improvement in your Kaposi's sarcoma including flattening, lightening and even shrinkage of the cancer. 
Zdravilo Caelyx se uporablja tudi za izboljšanje stanja pri Kaposijevem sarkomu, vključno s sploščenjem rakavih poškodb, njihovo posvetlitvijo in celo zmanjšanjem velikosti.
Prior to Caelyx administration, evaluate hepatic function using conventional clinical laboratory tests such as ALT/AST, alkaline phosphatase, and bilirubin. 
Pred uporabo zdravila Caelyx morate oceniti delovanje jeter z običajnimi kliničnimi laboratorijskimi testi, npr. ALT/AST, alkalno fosfatazo in bilirubinom.
PPE*, alopecia, rash PPE* 
PPE*, alopecija, izpuščaj
Avoid becoming pregnant while you or your partner are taking Caelyx and in the six months following discontinuation of Caelyx treatment. 
Pazite, da ne zanosite v času, ko vi ali vaš partner prejemate zdravilo Caelyx, in še šest mesecev po prekinitvi zdravljenja z njim.
In nearly all patients, Caelyx treatment can be resumed after all symptoms have resolved without recurrence. 
Pri skoraj vseh bolnikih lahko zdravljenje z zdravilom Caelyx nadaljujete, ko izginejo vsi simptomi, in ti se potem ne ponovijo.
In a subset of 410 patients with ovarian cancer, clinically significant laboratory abnormalities occurring in clinical trials with Caelyx included increases in total bilirubin (usually in patients with liver metastases) (5%) and serum creatinine levels (5%). 
V podskupini 410 bolnic z rakom jajčnikov so bili med klinično pomembnimi nenormalnimi laboratorijskimi izvidi, ki so se pojavili v kliničnih preskušanjih z zdravilom Caelyx, zvečanje koncentracije celokupnega bilirubina (običajno pri bolnikih z jetrnimi metastazami) (5%) in serumske koncentracije kreatinina (5%).
The treatment HR for PFS when adjusted for prognostic variables was consistent with PFS for the ITT population. 
Terapevtski HR za PFS, korigiran z upoštevanjem prognostičnih spremenljivk, je bil v skladu z vrednostjo PFS za populacijo, ki naj bi jo zdravili ("intent-to-treat").
Population pharmacokinetic data (in the range of creatinine clearance tested of 30-156 ml/min) demonstrate that Caelyx clearance is not influenced by renal function. 
Podatki populacijske farmakokinetike (v testiranem razponu očistka kreatinina od 30 do 156 ml/min) kažejo, da delovanje ledvic ne vpliva na ledvični očistek zdravila Caelyx.
Some of these abnormalities may have been related to the underlying HIV infection and not Caelyx. 
Nekateri od teh nenormalnih laboratorijskih izvidov so lahko posledica okužbe s HIV in ne uporabe zdravila Caelyx.
Rare side effects (may affect up to 1 in 1,000 people) - blue colour to the skin and mucosa caused by low oxygen in the blood; - patches of skin thickening. 
Redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 bolnikov) - modro obarvana koža in sluznice zaradi nizke vsebnosti kisika v krvi, - zadebelitev delov kože.
Do not use Caelyx - if you are allergic to doxorubicin hydrochloride, peanut or soya, or any of the ingredients of this medicine (listed in section 6). 
Ne uporabljajte zdravila Caelyx - če ste alergični na doksorubicinijev klorid, arašide, sojo ali katero koli sestavino tega zdravila
Do not use material that shows evidence of precipitation or any other particulate matter. 
Ne uporabljajte pripravka, ki kaže znake obarjanja ali vsebuje kakršnekoli druge vidne delce.
The CHMP recommends that the terms of the Marketing Authorisation(s) should be varied. 
Odbor CHMP zato priporoča spremembo pogojev dovoljenja (dovoljenj) za promet z zdravilom.
Although local necrosis following extravasation has been reported very rarely, Caelyx is considered to be an irritant. 
Čeprav so o lokalni nekrozi po ekstravazaciji poročali zelo redko, zdravilo Caelyx velja za dražečo snov.
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). 
Izdaja zdravila je le s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
Week 6 
6. teden
Renal toxicity has been observed with even lower single doses of doxorubicin HCl in rats and rabbits. 
Ledvično toksičnost pa so opažali tudi pri manjših enkratnih odmerkih doksorubicin klorida pri podganah in kuncih.
- In combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. 
- V kombinaciji z bortezomibom za zdravljenje napredovalega diseminiranega plazmocitoma pri bolnikih, ki so pred tem že prejeli najmanj eno vrsto predhodnega zdravljenja in so bodisi že imeli presaditev kostnega mozga ali pa niso primerni zanjo.
Infusion reactions rarely recur after the first treatment cycle. 
Infuzijske reakcije se le redko ponovijo po prvem krogu kemoterapije.
In the pivotal trial in patients with ovarian cancer treated at a dose of 50 mg/m myelosuppression was generally mild to moderate, reversible, and was not associated with episodes of neutropaenic infection or sepsis. 
V osrednji raziskavi pri bolnicah z rakom jajčnikov, zdravljenih z odmerkom 50 mg/m2, je bila mielosupresija na splošno blaga do zmerna in reverzibilna ter ni bila povezana z epizodami okužb zaradi nevtropenije ali sepso.
The cumulative dose at which cardiotoxicity would become a concern for these AIDS-KS patients (> 400 mg/m2) would require more than 20 courses of Caelyx therapy over 40 to 60 weeks. 
Za dosego kumulativnega odmerka (> 400 mg/m2), pri katerem bi kardiotoksičnost pri teh bolnikih postala problem, bi bilo potrebnih več kot 20 krogov zdravljenja z zdravilom Caelyx v obdobju 40 do 60 tednov.
This is probably the result of intercalation of the anthracycline between adjacent base pairs of the DNA double helix thus preventing their unwinding for replication. 
Do zavore verjetno pride zaradi vrivanja antraciklina med sosednje bazne pare dvojne vijačnice DNA, kar prepreči njeno razvitje, potrebno za podvojitev.
Furthermore, based on the pooled analysis of 4,231 patients across indications, the SmPC should be updated to in order to better detail the risk of cardiotoxicity associated with Caelyx. 
Na podlagi analize združenih podatkov pri 4.321 bolnikih glede na indikacije, je treba posodobiti Povzetek glavnih značilnosti zdravila (SmPC), z namenom natančnejše opredelitve tveganja za pojav kardiotoksičnost pri uporabi zdravila Caelyx.
Grade 1 (mild erythema, swelling, or desquamation not interfering with daily activities) 
Stopnja 1 (blag eritem, otekanje ali deskvamacija, ki ne ovira vsakodnevnih dejavnosti)
The evaluation tests and methods mentioned above concerning the monitoring of cardiac performance during anthracycline therapy are to be employed in the following order: ECG monitoring, measurement of left ventricular ejection fraction, endomyocardial biopsy. 
Omenjene preiskave in postopke za oceno delovanja srca in njegovo spremljanje med zdravljenjem z antraciklini uporabljajte v naslednjem vrstnem redu: spremljanje EKG, merjenje iztisnega deleža levega prekata, endomiokardna biopsija.
Redose unless patient has experienced a previous grade 3 or 4 skin toxicity, in which case wait an additional week 
Ponovite odmerek, razen če ni bolnik prej imel kožne toksičnosti 3. ali 4. stopnje; v tem primeru počakajte še en teden.
The pharmacokinetics of Caelyx over the dose range of 10 mg/m2 to 60 mg/m2 was best described by a two compartment non-linear model with zero order input and Michaelis-Menten elimination. 
Farmakokinetiko zdravila Caelyx v odmernem območju od 10 do 60 mg/m2 najbolje opiše dvoprostorni nelinearni model z vnosom ničelnega reda in MichaelisMentenovim izločanjem.
Clinically significant laboratory abnormalities frequently ( 5%) occurred including increases in alkaline phosphatase; AST and bilirubin which were believed to be related to the underlying disease and not Caelyx. 
Pogosto ( 5%) so se pojavljali klinično pomembni nenormalni laboratorijski izvidi, vključno z zvišanjem koncentracije alkalne fosfataze ter zvišanjem koncentracije AST in bilirubina, za katera menijo, da sta posledica osnovne bolezni in ne uporabe zdravila Caelyx.
Do not dose; if 2 or more doses are not given in a cycle, reduce dose by 25% in following cycles. 
Ne infundirajte, če v posameznem krogu bolniku niste dali dveh ali več odmerkov, mu zmanjšajte odmerek za 25% v naslednjih krogih.
Leukopaenia is the most frequent undesirable effect experienced with Caelyx in this population; neutropaenia, anaemia and thrombocytopaenia have been observed. 
Levkopenija je najpogostnejši neželeni učinek zdravila Caelyx v tej populaciji; ugotavljali so tudi nevtropenijo, anemijo in trombocitopenijo.
Solid tumour patients: in a larger cohort of 929 patients with solid tumours (including breast cancer and ovarian cancer) predominantly treated at a dose of 50 mg/m2 every 4 weeks, the safety profile and incidence of adverse effects are comparable to those of the patients treated in the pivotal breast cancer and ovarian cancer trials. 
Bolnice s solidnimi tumorji: v večji kohorti 929 bolnikov s solidnimi tumorji (vključno z rakom dojk in rakom jajčnikov), ki so jih zdravili pretežno z odmerkom 50 mg/m vsake 4 tedne, sta bila profil neželenih učinkov zdravila in incidenca neželenih učinkov podobna kot pri bolnicah, zdravljenih v osrednjih preskušanjih raka dojk in raka jajčnikov.
The pegylated liposomes also have a low permeability lipid matrix and internal aqueous buffer system that combine to keep doxorubicin hydrochloride encapsulated during liposome residence time in circulation. 
Pegilirani liposomi imajo tudi lipidni matriks majhne permeabilnosti in notranji vodni pufrski sistem, ki skupaj ohranjata doksorubicinijev klorid inkapsuliran, dokler liposomi krožijo v krvi.
Caelyx is administered as an intravenous infusion. 
Zdravilo Caelyx se uporablja v obliki intravenske infuzije.
The dosage can be increased to full dose for subsequent cycles if tolerated. 
Odmerek smete v naslednjih krogih povečati do polnega odmerka, če bolnik to dobro prenaša.
If a test result indicates possible cardiac injury associated with Caelyx therapy, the benefit of continued therapy must be carefully weighed against the risk of myocardial injury. 
Če izvid pokaže možno okvaro srca v povezavi z zdravljenjem z zdravilom Caelyx, morate skrbno pretehtati koristnost nadaljnjega zdravljenja v primerjavi s tveganjem za okvaro miokarda.
To minimise the risk of infusion reactions, the initial dose is administered at a rate no greater than 1 mg/minute. 
Da bi kar najbolj zmanjšali nevarnost infuzijskih reakcij, hitrost dajanja začetnega odmerka ne sme preseči 1 mg/minuto.
Caelyx is also used to treat cancer of the ovary. 
Zdravilo Caelyx se uporablja tudi za zdravljenje raka jajčnikov.
Guidelines for Caelyx dose modification secondary to these adverse effects are provided in the tables below. 
Smernice za prilagajanje odmerka zdravila Caelyx v primeru pojava teh neželenih učinkov so podane v spodnjih preglednicah.
Many patients treated with Caelyx have baseline myelosuppression due to such factors as their pre-existing HIV disease or numerous concomitant or previous medications, or tumours involving bone marrow. 
Številni bolniki, zdravljeni z zdravilom Caelyx, imajo mielosupresijo že na začetku zdravljenja zaradi dejavnikov, kot so npr. obstoječa okužba s HIV, številna sočasna ali predhodno uporabljena zdravila ali pa infiltracija kostnega mozga.
Caelyx contains less than 1 mmol sodium (23 mg) per dose, that is to say ‘essentially sodium-free'. 
Zdravilo Caelyx vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar v bistvu pomeni ‘brez natrija'.
The table for haematological toxicity (Table 3) provides the schedule followed for dose modification in clinical trials in the treatment of patients with breast or ovarian cancer only. 
Preglednica za hematološko toksičnost (Preglednica 3) podaja shemo za prilagajanje odmerka, uporabljeno v kliničnih študijah le pri zdravljenju bolnic z rakom dojk ali rakom jajčnikov.
If the patient experiences early symptoms or signs of infusion reaction (see sections 4.4 and 4.8), immediately discontinue the infusion, give appropriate premedications (antihistamine and/or short acting corticosteroid) and restart at a slower rate. 
Če se pojavijo zgodnji simptomi ali znaki infuzijske reakcije (glejte poglavji 4.4. in 4.8), infuzijo takoj prekinite, bolniku dajte ustrezno premedikacijo (antihistaminik in/ali kratkodelujoči kortikosteroid) in nato nadaljujte infuzijo z manjšo hitrostjo.
5 How to store Caelyx Contents of the pack and other information 
Shranjevanje zdravila Caelyx Vsebina pakiranja in dodatne informacije
Similar dermal lesions, which are described as palmar-plantar erythrodysesthesia were also observed in patients after long-term intravenous infusion (see section 
Podobne kožne lezije, ki jih opisujejo kot palmo-plantarno eritrodizestezijo, so opažali tudi pri bolnikih po dolgotrajnih intravenskih infuzijah (glejte poglavje 4.8).
Caelyx contains a medicine which is able to interact with cells in such a way as to selectively kill cancer cells. 
Zdravilo Caelyx vsebuje zdravilno učinkovino, ki deluje tako, da selektivno uničuje rakave celice.
Treatment will include administration of antibiotics, platelet cell transfusions, use of factors which stimulate production of white blood cells and symptomatic treatment of mouth sores. 
Zdravljenje bo vključevalo uporabo obsega antibiotikov, transfuzij trombocitov, dajanje faktorjev, ki spodbujajo nastajanje levkocitov in simptomatsko zdravljenje razjed v ustih.
Ovarian cancer n=512 
Rak jajčnikov n=512
Toxicity grade at current assessment 
Trenutna ocena stopnje toksičnosti
If the patient experiences early symptoms or signs of infusion reaction, immediately discontinue the infusion, give appropriate premedications (antihistamine and/or short acting corticosteroid) and restart at a slower rate. 
Če se pri bolniku pojavijo zgodnji simptomi ali znaki infuzijske reakcije, infuzijo takoj prekinite, mu dajte ustrezno premedikacijo (antihistaminik in/ali kratkodelujoči kortikosteroid) in nato infuzijo nadaljujte z manjšo hitrostjo.
The active ingredient of Caelyx is doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius. 
Učinkovina zdravila Caelyx je doksorubicinijev klorid, ki je citotoksičen antraciklinski antibiotik, pridobljen iz Streptomyces peucetius var. caesius.
EU/1/96/011/001 (1 vial) EU/1/96/011/002 (10 vials) 
EU/1/96/011/001 (1 viala) EU/1/96/011/002 (10 vial)
After dilution: - Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C to 8°C. 
Po razredčenju: - Zdravilo je med uporabo kemično in fizikalno stabilno 24 ur pri temperaturi 2 °C do 8 °C.
EU/1/96/011/003 (1 vial) EU/1/96/011/004 (10 vials) 
EU/1/96/011/003 (1 viala) EU/1/96/011/004 (10 vial)
Caelyx may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline). 
- Zdravilo Caelyx lahko uporabljate kot sistemsko kemoterapijo prve izbire ali kot kemoterapijo druge izbire pri bolnikih, ki imajo z aidsom povezan Kaposijev sarkom in bolezen, ki je napredovala kljub predhodni kombinirani sistemski kemoterapiji z vsaj dvema od naslednjih citostatikov: alkaloid vinke, bleomicin in standardni doksorubicin (ali kakšen drug antraciklin) ter pri tistih bolnikih, ki so slabo prenašali takšno predhodno kombinirano sistemsko kemoterapijo.
Decrease dose by 25%; return to 4 week interval or withdraw patient per physician's assessment 
Zmanjšajte odmerek za 25%; vrnite se na 4-tedenski razmik ali prenehajte s to terapijopo presoji zdravnika
At cumulative doses greater than 450 mg/m2 there were no cardiac events with Caelyx. 
Pri kumulativnih odmerkih, večjih od 450 mg/m2, ni bilo pri zdravilu Caelyx nobenih kardialnih sopojavov.
The plasma pharmacokinetics of Caelyx in humans differ significantly from those reported in the literature for standard doxorubicin hydrochloride preparations. 
Farmakokinetika zdravila Caelyx v plazmi pri ljudeh se bistveno razlikuje od farmakokinetike, opisane v literaturi za standardne pripravke doksorubicinijevega klorida.
Infusion-associated reactions 
Infuzijske reakcije
Respiratory undesirable effects commonly occurred in clinical studies of Caelyx and may be related to opportunistic infections (OI's) in the AIDS population. 
Neželeni učinki na dihala so bili v kliničnih študijah z zdravilom Caelyx pogosti in bi lahko bili povezani z oportunističnimi okužbami pri bolnikih z aidsom.
Vascular disorders uncommon venous thromboembolism, including thrombophlebitis, venous thrombosis and pulmonary embolism 
Žilne bolezni občasni venski trombembolizem, vključno s tromboflebitisom, vensko trombozo in pljučno embolijo
Based on the review of the safety data of pegylated liposomal doxorubicin hydrochloride (Caelyx), a signal of lichenoid keratosis was detected with a total of 10 cases reported. 
Na podlagi pregleda podatkov o varnosti doksorubicinijevega klorida v pegiliranem liposomskem pripravku (zdravilo Cealyx), so pri 10 poročanih primerih ugotovili varnostni signal za lihenoidno keratozo.
Breast cancer/Ovarian cancer Caelyx is administered intravenously at a dose of 50 mg/m once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment. 
Zdravilo Caelyx se daje intravensko v odmerku 50 mg/m2 enkrat na vsake 4 tedne, dokler bolezen ne napreduje in bolnica dobro prenaša zdravljenje.
A phase III randomised study of Caelyx versus doxorubicin in patients with metastatic breast cancer was completed in 509 patients. 
Randomizirano raziskavo faze III, v kateri so zdravilo Caelyx primerjali s standardnim doksorubicinom pri bolnikih z metastatskim rakom dojk, je zaključilo 509 bolnikov.
The use of any diluent other than 5% (50 mg/ml) glucose solution for infusion, or the presence of any bacteriostatic agent such as benzyl alcohol may cause precipitation of Caelyx. 
Uporaba katerega koli drugega vehikla kot 5% (50 mg/ml) raztopine glukoze za infundiranje oz. prisotnost kakršnegakoli bakteriostatika, npr. benzil alkohola, lahko povzroči obarjanje zdravila Caelyx.
Do not dose this cycle if before day 4; if after day 4 reduce next dose by 25% in the following cycles if bortezomib is reduced for haematologic toxicity. 
V tem krogu ne infundirajte zdravila, če se to pojavi pred 4. dnevom, po 4. dnevu pa bolniku zmanjšajte naslednji odmerek za 25% v naslednjih krogih, če je bil odmerek bortezomiba zmanjšan zaradi hematološke toksičnosti.
There was a significant improvement in the primary endpoint of time to progression (TTP) for patients treated with combination therapy of Caelyx plus bortezomib compared to patients treated with bortezomib monotherapy as indicated by a risk reduction (RR) of 35% (95% CI: 21-47%), p < 0.0001, based on 407 TTP events. 
Opazno je bilo bistveno izboljšanje kar zadeva primarni končni rezultat, ki je bil čas do napredovanja bolezni (TTP) pri bolnikih, ki so bili zdravljeni s kombinirano terapijo z zdravilom Caelyx in bortezomibom, v primerjavi s tistimi, ki so prejemali bortezomib v monoterapiji; to so ugotovili na podlagi zmanjšanja tveganja (RR) za 35% (95% interval zaupanja IZ; od 21 do 47%), p < 0,0001 na osnovi 407 TTP dogodkov.
Maximum plasma concentration* (µg/ml) Plasma clearance (l/h/m Volume of distribution (l/m AUC (µg/mlh) 
Največja koncentracija v plazmi* (μg/ml) Plazemski očistek (l/h/m Volumen porazdelitve (l/m AUC (μg/ml∙h) λ1 razpolovni čas (h) λ2 razpolovni čas (h)
Caelyx is also used in combination with another medicine, bortezomib, to treat multiple myeloma, a cancer of the blood in patients who have received at least 1 prior therapy. 
Zdravilo Caelyx uporabljamo tudi v kombinaciji z drugim zdravilom, bortezomibom, za zdravljenje diseminiranega plazmocitoma, vrste krvnega raka pri bolnikih, ki so že prejeli najmanj 1 vrsto predhodnega zdravljenja.
Caelyx contains soya oil and sodium 
Zdravilo Caelyx vsebuje sojino olje in natrij
In studies performed after the repeated administration of Caelyx to rats and dogs, serious dermal inflammations and ulcer formations were observed at clinically relevant dosages. 
V raziskavah večkratnega dajanja zdravila Caelyx podganam in psom so pri klinično relevantnih odmerkih opažali resna kožna vnetja in nastajanje razjed.
- Partially used vials must be discarded. 
- Delno porabljene viale morate zavreči.
The most frequently reported (medicine-related treatment-emergent) adverse events in combination therapy (Caelyx + bortezomib) were nausea (40%), diarrhoea (35%), neutropaenia (33%), thrombocytopaenia (29%), vomiting (28%), fatigue (27%), and constipation (22%). 
Najpogosteje poročani neželeni učinki (ki so bili povezani s prejemanjem zdravil in so se pojavili med zdravljenjem z njimi) pri zdravljenju z zdravilom Caelyx v kombinaciji z bortezomibom so bili slabost (40%), driska (35%), nevtropenija (33%), trombocitopenija (29%), bruhanje (28%), utrujenost (27%) in zaprtje (22%).
Mucositis (23% vs. 13%; grade 3/4 4% vs. 2%), and stomatitis (22% vs. 15%; grade 3/4 5% vs. 2%) were reported more commonly with Caelyx than with doxorubicin. 
O mukozitisu (23% in 13%, 3. do 4. stopnja 4% in 2%) in stomatitisu (22% in 15%, 3. do 4. stopnja 5% in 2%) so poročali pogosteje pri zdravilu Caelyx kot pri standardnem doksorubicinu.
Persistent severe myelosuppression, may result in superinfection or haemorrhage. 
Dolgotrajna huda mielosupresija lahko vodi do sekundarnih okužb ali krvavitev.
The haematological toxicity for ovarian cancer patients is less severe than in the AIDS-KS setting (see section for ovarian cancer patients above). 
Hematološki toksični učinki pri bolnicah z rakom jajčnikov so manj resni kot pri bolnikih, ki imajo z aidsom povezan Kaposijev sarkom (glejte poglavje o bolnicah z rakom jajčnikov).
Stomatitis was reported more frequently in the combination therapy group (16%) than in the monotherapy group (3%), and most cases were grade 2 or less in severity. 
O stomatitisu so poročali pogosteje v skupini, ki je prejemala kombinirano zdravljenje (16%) kot v skupini, ki je prejamala monoterapijo (3%), in večina primerov je bila po jakosti 2. stopnje ali manj.
The dose is repeated as long as you respond satisfactorily and tolerate treatment. 
Infuzije bodo ponavljali tako dolgo, dokler se boste zadovoljivo odzivali na zdravljenje in ga boste dobro prenašali.
Guidelines for Caelyx dose modification 
Smernice za prilagajanje odmerka zdravila Caelyx
Animal studies indicate that administration of doxorubicin hydrochloride as a liposomal formulation reduces the potential for extravasation injury. 
Raziskave pri živalih kažejo, da uporaba liposomskega pripravka doksorubicinijevega klorida zmanjša nevarnost ekstravazacijske poškodbe.
Because of the potential for bone marrow suppression, periodic blood counts must be performed frequently during the course of Caelyx therapy, and at a minimum, prior to each dose of Caelyx. 
Zaradi nevarnosti mielosupresije morate med zdravljenjem z zdravilom Caelyx pogosto in redno opravljati preiskave krvne slike, vsaj pred vsakim odmerkom zdravila.